FORDEN v. ALLERGAN PLC

CourtDistrict Court, D. New Jersey
DecidedJanuary 25, 2021
Docket2:16-cv-09449
StatusUnknown

This text of FORDEN v. ALLERGAN PLC (FORDEN v. ALLERGAN PLC) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
FORDEN v. ALLERGAN PLC, (D.N.J. 2021).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

IN RE ALLERGAN Civil Action No. 2:16-9449 (KSH) (CLW) GENERIC DRUG PRICING SECURITIES LITIGATION OPINION AND ORDER

I. Introduction This matter comes before the Court on the letter motion of Lead Plaintiffs Sjunde AP- Fonden and Union Asset Management Holding AG (“Plaintiffs”) seeking, under Local Rule 37.1 and FED. R. CIV. P. 26 and 45(b), to quash a subpoena (the “Subpoena”) issued by Defendants to non-party the City of Providence, Rhode Island (“Providence”) and/or a protective order (D.E. 152).1 Providence joined in Plaintiffs’ motion (D.E. 157);2 Defendants submitted opposition (D.E. 160); and Providence submitted a declaration in further support (D.E. 165), to which Defendants responded (D.E. 166). For the reasons stated below, Plaintiffs’ motion is granted in part and denied in part. The Court will grant a protective order as to the portion of the Subpoena seeking a deposition and deny Plaintiffs’ motion in all other respects. II. Background Plaintiffs brought this securities class action in December 2016. D.E. 1. Broadly, the action grows from Defendants’ alleged participation in a generic pharmaceutical price-fixing conspiracy which has yielded numerous state and federal investigations and congressional inquiries dating

1 Under Rule 45(d)(3)(A), a court my quash or modify a subpoena that “(i) fails to allow a reasonable time to comply; (ii) requires a person to comply beyond the geographical limits specified in Rule 45(c); (iii) requires disclosure of privileged or other protected matter, if no exception or waiver applies; or (iv) subjects a person to undue burden.” Local Rule 37.1 governs discovery motions generally.

2 The Court will refer to Plaintiffs’ and Providence’s applications as “Plaintiffs’ motion.” back to January 2014. D.E. 82 at ¶¶ 2, 10-14, 21-25. As news of these developments became public throughout 2015 and 2016, defendant Allergan plc’s (“Allergan”) stock price fell. Id. at ¶¶ 15-17. Plaintiffs allege that—in addition to Defendants’ underlying anti-competitive activities— throughout the class period of October 29, 2013 through November 2, 2016, Defendants made

fraudulent omissions and misrepresentations as to Allergan’s involvement in the alleged price- fixing scheme and the company’s overall financial stability. Id. at p. 6 and ¶¶ 26-32. They claim damages arising from the “precipitous decline in the market value of Allergan securities”, and seek recovery under Sections 10(b), 14(a), and 20(a) of the Securities Exchange Act of 1934 and SEC Rules 10b-5 and 14a-9. Id. at ¶¶ 1, 33. Following consolidation, amended complaints, and an unsuccessful motion to dismiss, in March 2020 Plaintiffs filed a class certification motion, which is pending. See D.E. 36, 47, 82, 87, 124, 125, 143. Plaintiffs seek to certify the following class (with certain exceptions): (i) as to claims arising under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (“Exchange Act”), all persons and entities who purchased or otherwise acquired Allergan common and/or preferred stock between October 29, 2013 and November 2, 2016, both dates inclusive (the “Class Period”), and were injured thereby; (ii) as to claims arising under Section 14(a) of the Exchange Act in connection with the Forest Merger, all persons and entities who held Forest common stock as of May 2, 2014, and were entitled to vote on the merger between Allergan and Forest, and were damaged thereby; and (iii) as to claims arising under Section 14(a) of the Exchange Act in connection with the Actavis Merger, all persons and entities who held Allergan, Inc. common stock as of January 22, 2015, and were entitled to vote on the merger between Allergan and Actavis, and were damaged thereby.

D.E. 143-1 at 8.

Separate from this action, in May 2016, Providence sued Allergan for the same alleged antitrust violations underlying this matter. City of Providence, Rhode Island v. Allergan, et al., 01:16-CV-00214 (D.R.I.) at D.E. 1. That action arises from Providence’s purchase of two of Allergan’s generic drugs which underwent “astonishing” price increases; according to Providence, due to Allergan’s anti-competitive activity. Id. at ¶¶ 1-6. Providence’s lawsuit was consolidated with several others and is currently proceeding as a multi-district litigation in the U.S. District Court for the Eastern District of Pennsylvania. See In Re: Generic Pharmaceuticals Pricing

Antitrust Litig., 02:16-MD-02724 (E.D. Pa.) (the “Antitrust MDL”). In or around May 2020, Defendants served the Subpoena upon Providence.3 D.E. 152-1. The Subpoena seeks deposition testimony and documents concerning (i) Providence’s purchase of Allergan securities; and (ii) Providence’s awareness of, and action concerning, Allergan’s alleged anti-competitive activities. Id. Providence responded, objecting to the requests and declining to provide any documents. D.E. 160-1. After attempts at resolving these issues failed, D.E. 152-3, 4, 5, Plaintiffs filed the instant motion. III. Defendants’ Requests for Absent Class Member Discovery a. Absent Class Member Discovery Generally As Providence is not a named party in this class action, but, as discussed below, appears to

fall within the definition for the proposed class, much of the parties’ briefing centers on the issue of absent class member discovery. It is settled that “[a]bsent [i.e., non-representative] class members are not parties for discovery purposes under Rules 33 and 34. As a result, a strong showing is typically required before discovery of absent class members is compelled.” Guenther v. Sedco, Inc., 1998 U.S. Dist. LEXIS 19901, at *17-18 (S.D.N.Y. Dec. 21, 1998) (citation omitted); see, e.g., Phillips Petroleum Co. v. Shutts, 472 U.S. 797, 810 (1985) (“[A]n absent class- action plaintiff is not required to do anything. He may sit back and allow the litigation to run its

3 Plaintiffs’ motion also addresses a subpoena issued to another non-party, the NECA-IBEW Welfare Trust Fund; however, that subpoena has been withdrawn, thus mooting that portion of the motion. See D.E. 159. course, content in knowing that there are safeguards provided for his protection.”); In re Lucent Techs. Sec. Litig., 2002 U.S. Dist. LEXIS 24973, at *6 (D.N.J. July 15, 2002) (absent class members “should be treated as passive class members and thus not subject to discovery”) (citing cases). The aversion toward absent class member discovery grows in large part from concerns that

defendants may use such devices “as a tactic to take undue advantage of the class members or as a stratagem to reduce the number of claimants.” See Brennan v. Midwestern United Life Ins. Co., 450 F.2d 999, 1005 (7th Cir. 1971), cert. denied, 405 U.S. 921 (1972). The “strong showing” needed to compel absent class member discovery is based on the test initially set forth in Brennan and later modified by various courts, most notably Clark v. Universal Builders, Inc., 501 F.2d 324 (7th Cir. 1974). Under Brennan, Clark, and their progeny, relevant considerations include whether: (i) the information requested is relevant to the decision of common questions; (ii) the requests are tendered in good faith and are not unduly burdensome; (iii) the information sought is unavailable from the class representative parties; (iv) the requests seek information on matters already known to defendants; (v) the requests are designed to take

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Merck & Co. v. Reynolds
559 U.S. 633 (Supreme Court, 2010)
Phillips Petroleum Co. v. Shutts
472 U.S. 797 (Supreme Court, 1985)
Basic Inc. v. Levinson
485 U.S. 224 (Supreme Court, 1988)
William Barnes v. The American Tobacco Company
161 F.3d 127 (Third Circuit, 1998)
Jaroslawicz v. Engelhard Corp.
724 F. Supp. 294 (D. New Jersey, 1989)
United States v. Litvak
889 F.3d 56 (Second Circuit, 2018)
On the House Syndication, Inc. v. Federal Express Corp.
203 F.R.D. 452 (S.D. California, 2001)
McPhail v. First Command Financial Planning, Inc.
251 F.R.D. 514 (S.D. California, 2008)
Blackie v. Barrack
524 F.2d 891 (Ninth Circuit, 1975)
Peil v. Speiser
806 F.2d 1154 (Third Circuit, 1986)
Baldwin & Flynn v. National Safety Associates
149 F.R.D. 598 (N.D. California, 1993)
McCarthy v. Paine Webber Group, Inc.
164 F.R.D. 309 (D. Connecticut, 1995)
Waters v. International Precious Metals Corp.
172 F.R.D. 479 (S.D. Florida, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
FORDEN v. ALLERGAN PLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/forden-v-allergan-plc-njd-2021.